Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients.
Publication
, Journal Article
Li, Y; Chen, P; Huang, X; Huang, H; Ma, Q; Lin, Z; Qiu, L; Ou, C; Liu, W
Published in: J Neuroimmunol
November 15, 2024
In our study, we investigated the impact of tacrolimus (TAC) on CD4+ T cell subsets in 41 AChR-MG patients over 12 weeks. Twenty-seven patients were classified as the response group (RG) (improved myasthenia gravis composite scores ≥3), while 14 were non-response. We found that TAC treatment significantly reduced Th17 and pathogenic Th17 cells, along with IL-17 levels in RG, while Th1 and Tfh cells slightly decreased without affecting Th2 or Treg subsets. This indicates that TAC's clinical benefits may be due to its inhibitory effect on the Th17 response, enhancing our insight into its immunomodulatory mechanisms in MG management.
Duke Scholars
Published In
J Neuroimmunol
DOI
EISSN
1872-8421
Publication Date
November 15, 2024
Volume
396
Start / End Page
578464
Location
Netherlands
Related Subject Headings
- Young Adult
- Th17 Cells
- Tacrolimus
- Receptors, Cholinergic
- Neurology & Neurosurgery
- Myasthenia Gravis
- Middle Aged
- Male
- Immunosuppressive Agents
- Humans
Citation
APA
Chicago
ICMJE
MLA
NLM
Li, Y., Chen, P., Huang, X., Huang, H., Ma, Q., Lin, Z., … Liu, W. (2024). Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients. J Neuroimmunol, 396, 578464. https://doi.org/10.1016/j.jneuroim.2024.578464
Li, Yingkai, Pei Chen, Xin Huang, Hao Huang, Qian Ma, Zhongqiang Lin, Li Qiu, Changyi Ou, and Weibin Liu. “Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients.” J Neuroimmunol 396 (November 15, 2024): 578464. https://doi.org/10.1016/j.jneuroim.2024.578464.
Li Y, Chen P, Huang X, Huang H, Ma Q, Lin Z, et al. Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients. J Neuroimmunol. 2024 Nov 15;396:578464.
Li, Yingkai, et al. “Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients.” J Neuroimmunol, vol. 396, Nov. 2024, p. 578464. Pubmed, doi:10.1016/j.jneuroim.2024.578464.
Li Y, Chen P, Huang X, Huang H, Ma Q, Lin Z, Qiu L, Ou C, Liu W. Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients. J Neuroimmunol. 2024 Nov 15;396:578464.
Published In
J Neuroimmunol
DOI
EISSN
1872-8421
Publication Date
November 15, 2024
Volume
396
Start / End Page
578464
Location
Netherlands
Related Subject Headings
- Young Adult
- Th17 Cells
- Tacrolimus
- Receptors, Cholinergic
- Neurology & Neurosurgery
- Myasthenia Gravis
- Middle Aged
- Male
- Immunosuppressive Agents
- Humans